These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22000685)

  • 1. [Prescription of ergot derivatives for lactation inhibition in France: Current practices].
    Mirkou A; Suchovsky D; Gouraud A; Gillet A; Bernard N; Descotes J; Vial T
    J Gynecol Obstet Biol Reprod (Paris); 2012 Apr; 41(2):167-73. PubMed ID: 22000685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
    BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the onset of lactation. Is cabergoline an alternative to bromocriptine?
    Prescrire Int; 2015 Nov; 24(165):276-7. PubMed ID: 26688910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey.
    Bernard N; Jantzem H; Becker M; Pecriaux C; Bénard-Laribière A; Montastruc JL; Descotes J; Vial T;
    BJOG; 2015 Aug; 122(9):1244-51. PubMed ID: 25761676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactation-inhibiting and prolactin-lowering effect of lisuride and bromocriptine: a comparative study.
    Van Dam LJ; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1981 Nov; 12(5):323-30. PubMed ID: 7333409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of lisuride and bromocriptine on inhibition of lactation and on serum prolactin levels: comparative double-blind study.
    Venturini PL; Horowski R; Maganza C; Morano S; Pedretti E; Ragni N; Semino F; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1981 May; 11(6):395-400. PubMed ID: 7018950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
    Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lactation inhibition with various dosages of lisuride--prolactin secretion and effectiveness].
    Strahl HJ; Göretzlehner G; Strahl S; Kunkel S
    Zentralbl Gynakol; 1985; 107(5):300-3. PubMed ID: 4039514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women.
    Bohnet HG; Kato K; De Moll H
    Obstet Gynecol; 1988 Jan; 71(1):53-5. PubMed ID: 3336541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
    Sentilhes L; Jeanneteau P; Parot-Schinkel E; Mercier MB; Descamps P
    Gynecol Obstet Fertil; 2014 Apr; 42(4):197-9. PubMed ID: 24456937
    [No Abstract]   [Full Text] [Related]  

  • 12. Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.
    Tulloch KJ; Dodin P; Tremblay-Racine F; Elwood C; Money D; Boucoiran I
    J Int AIDS Soc; 2019 Jun; 22(6):e25322. PubMed ID: 31183987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
    Shrateh ON; Kumar KA; Jawed A; Shuja MH; Shamsi HUR; Naasan M
    J Gynecol Obstet Hum Reprod; 2024 Jun; 53(6):102783. PubMed ID: 38554942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.
    Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG; Cozzi R; Chiodini P; Luccarelli G
    N Engl J Med; 1985 Sep; 313(11):656-9. PubMed ID: 4022058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lisuride on inhibition of lactation and serum prolactin.
    De Cecco L; Venturini PL; Ragni N; Rossato P; Maganza C; Gaggero G; Horowski R
    Br J Obstet Gynaecol; 1979 Nov; 86(11):905-8. PubMed ID: 508675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ergot drugs suppress plasma prolactin and lactation but not aggression in parturient mice.
    Mann M; Michael SD; Svare B
    Horm Behav; 1980 Dec; 14(4):319-28. PubMed ID: 6894290
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Lisuride on serum prolactin levels during puerperium.
    Venturini PL; Maganza C; Massimilla A; Campanella P; Rossato P; Ragni N; De Cecco L
    Acta Eur Fertil; 1979 Jun; 10(2):51-5. PubMed ID: 545976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and clinical results in administering lisuride for inhibiting lactation.
    Zanagnolo VL; Pollini F; Falsetti L; Gastaldi A
    Acta Eur Fertil; 1987; 18(1):21-4. PubMed ID: 3115024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.